Argenx
ARGX
#534
Rank
โ‚น3.252 T
Marketcap
โ‚น53,199
Share price
-0.35%
Change (1 day)
80.71%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Revenue for Argenx (ARGX)

Revenue in 2024 (TTM): โ‚น155.11 Billion

According to Argenx 's latest financial reports the company's current revenue (TTM ) is โ‚น158.50 Billion. In 2023 the company made a revenue of โ‚น102.08 Billion an increase over the revenue in the year 2022 that were of โ‚น33.98 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Argenx from 2013 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) โ‚น155.11 B51.94%
2023 โ‚น102.08 B200.36%
2022 โ‚น33.98 B
2019 โ‚น6.25 B206.83%
2018 โ‚น2.03 B-36.52%
2017 โ‚น3.20 B176.17%
2016 โ‚น1.16 B110.33%
2015 โ‚น0.55 B50.76%
2014 โ‚น0.36 B19.7%
2013 โ‚น0.30 B